Cantor Fitzgerald raises target for Amgen stock from USD 400 to USD 440
Published on 10/08/2026 at 15:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen (ISIN US0311621009) was trading at EUR 364.28 at Lang & Schwarz on October 8, 2026 at 3:40 p.m. CEST. Cantor Fitzgerald raised its Amgen price target from USD 400.00 to USD 440.00 on October 8, 2026 while maintaining a Neutral rating, according to GuruFocus. The quote was down 1.17 percent versus the prior close of EUR 368.60.
Three dated Amgen milestones
On August 4, 2026, Amgen reported USD 10.05 billion in second-quarter revenue and adjusted earnings per share of USD 6.29, according to MarketBeat. On October 7, 2026, Amgen joined a USD 30.00 million Series A financing for Arboretum LifeSciences, as Simply Wall St reported. On October 8, 2026, Cantor Fitzgerald set the USD 440.00 target while retaining its Neutral rating, according to GuruFocus.
What does the target change mean
The new target is 10.00 percent above Cantor Fitzgerald's former USD 400.00 level, but the Neutral rating keeps the analyst view cautious. Amgen's Nasdaq quote was last at USD 408.64 on October 8, 2026 at 9:52 a.m. ET, putting the USD 440.00 target 7.67 percent above that quote. This contrast matters because the target increase recognizes portfolio strength while the rating does not call for an outright bullish stance.
Revenue growth meets a later test
The second-quarter revenue figure was 9.50 percent above the prior-year period, while adjusted earnings per share of USD 6.29 exceeded the USD 5.62 consensus cited by MarketBeat. The investment in Arboretum links Amgen to genetic testing data, while pipeline execution remains tied to future programs including MariTide. For investors, the key tension is visible in the numbers: operating momentum improved in the second quarter, yet Cantor's Neutral rating places greater weight on valuation and execution risk.
Next reporting date
WallStreetZen lists November 3, 2026 as Amgen's next earnings date. That report will give investors a new test of whether the USD 10.05 billion second-quarter revenue base can support the higher analyst target.
Amgen stock stays below its prior close
Amgen was trading at EUR 364.28 at Lang & Schwarz on October 8, 2026 at 3:40 p.m. CEST, minus 1.17 percent versus the Lang & Schwarz prior close of EUR 368.60 on October 7, 2026. The Nasdaq quote was last at USD 408.64 on October 8, 2026 at 9:52 a.m. ET. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.
Amgen stock facts
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Primary exchange: NASDAQ
- Price Lang & Schwarz as of October 8, 2026, 3:40 p.m. CEST: EUR 364.28
- Change versus prior close: minus 1.17 percent
- Prior close Lang & Schwarz October 7, 2026: EUR 368.60
- Market capitalization: USD 220.5 billion as of October 8, 2026
- 52-week range: USD 288.00-447.03 as of October 8, 2026
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: November 3, 2026
Market context: Market report Nasdaq Composite.
